Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

ClinicalTrials.gov ID: NCT00003810

Public ClinicalTrials.gov record NCT00003810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Gemcitabine and Docetaxel in Pancreatic Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more that one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and docetaxel in treating patients who have locally advanced or metastatic cancer of the pancreas.

Study identification

NCT ID
NCT00003810
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 11, 1999 (Actual)
Primary completion
May 2002 (Actual)
Completion
Not listed
Last update posted
Jun 15, 2023

Started 1999

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Indiana University Cancer Center Indianapolis Indiana 46202-5265 —
Greater Baltimore Medical Center and Cancer Center Baltimore Maryland 21204 —
Johns Hopkins Oncology Center Baltimore Maryland 21287 —
New England Medical Center Hospital Boston Massachusetts 02111 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
CCOP - Missouri Valley Cancer Consortium Omaha Nebraska 68131 —
Veterans Affairs Medical Center - Nashville Nashville Tennessee 37212 —
Vanderbilt Cancer Center Nashville Tennessee 37232-6838 —
Veterans Affairs Medical Center - Madison Madison Wisconsin 53705 —
University of Wisconsin Comprehensive Cancer Center Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2023 · Synced Oct 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00003810 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →